Peter Farrell - ResMed Insider

RMD -- USA Stock  

USD 102.98  2.05  2.03%

  Chairman
Dr. Peter Farrell, Ph.D. is NonExecutive Chairman of the Board, Founder of the Company. Dr. Farrell also served as chief executive officer from July 1990 until December 2007, and from February 2011 until March 2013. Dr. Farrell served as executive chairman of the board from December 2007 until February 2011, and from March 2013 through December 2013. Since January 1, 2014, he was a nonofficer employee of ResMed. From July 1984 to June 1989, Dr. Farrell served as vice president, research and development at various subsidiaries of Baxter International, Inc., and from August 1985 to June 1989, he also served as managing director of the Baxter Center for Medical Research Pty Ltd., a Baxter subsidiary. From January 1978 to December 1989, he was foundation director of the Graduate School for Biomedical Engineering at the University of New South Wales, where he currently serves as a visiting professor and as chairman of the UNSW Centre for Innovation and Entrepreneurship. He also serves on the Visiting Committee of the Health Sciences Technology Program at the Massachusetts Institute of Technology and on the MIT Dean of Engineerings Advisory Council
Age: 74  Chairman Since 2014  Ph.D    
858-836-5000  http://www.resmed.com
Farrell serves on two faculty advisory boards at the University of California, San Diego: the Rady Business School and the Jacobs Engineering School. He holds a B.E. in chemical engineering with honors from the University of Sydney, an S.M. in chemical engineering from the Massachusetts Institute of Technology, a Ph.D. in chemical engineering and bioengineering from the University of Washington, Seattle and a D.Sc. from the University of New South Wales for research contributions in the field of treatment with the artificial kidney. Since 2005, Dr. Farrell was a director of NuVasive, Inc., a NASDAQlisted company which develops and markets products for the surgical treatment of spine disorders. From 2007 through 2014, he was the nonexecutive chairman of the board of QRx Pharma, an ASXlisted specialty pharmaceutical company.

Peter Farrell Latest Insider Activity

Management Efficiency

The company has Return on Asset of 10.72 % which means that on every $100 spent on asset it made $10.72 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.7 % implying that it generated $15.7 on every 100 dollars invested.
The company has 281.45 M in debt with debt to equity (D/E) ratio of 13.6 . This implies that the company may be unable to create cash to meet all of its financial commitments. ResMed has Current Ratio of 2.05 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Found 10 records

CHAIRMAN Since

Andrew EckertVarian Medical Systems
2014
William ParfetStryker Corporation
2014
Vernon LoboEquillium
N/A
James CullenAgilent Technologies
2017
Timothy GuertinVarian Medical Systems
2012
Benson SmithTeleflex Incorporated
2017
Kevin LoboStryker Corporation
2018
Yuen KamChina Cord Blood Corporation
2012
Isaiah HarrisCigna Corporation
2009
Bret WiseDENTSPLY SIRONA
2016

Entity Summary

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in USA and is traded on New York Stock Exchange. It employs 5940 people.ResMed (RMD) is traded on New York Stock Exchange in USA. It is located in 9001 Spectrum Center Boulevard and employs 5,940 people.

ResMed Leadership Team

John Wareham, Independent Director
Ronald Taylor, Lead Independent Director
Rob Douglas, President COO
Christopher Roberts, Independent Director
Gary Pace, Independent Director
Chris Roberts, Independent Director
Robert Douglas, Pres and COO
Agnes Lee, Senior Director - Investor Relations
Carol Burt, Independent Director
Rich Sulpizio, Independent Director
Peter Farrell, Non-Executive Chairman of the Board
Jim Hollingshead, President - Americas
Brett Sandercock, CFO and Principal Accounting Officer
Ron Taylor, Lead Independent Director
Don Darkin, President - Sleep-disordered Breathing Strategic Business Unit
Jack Wareham, Independent Director
Anne Reiser, President Europe
Karen Drexler, Director
Raj Sodhi, President ? Software as a Service (SaaS) Business and CTO
David Pendarvis, Chief Admin. Officer, Global General Counsel and Secretary
Richard Sulpizio, Independent Director
Michael Farrell, CEO and Director
Richard McHale, President ? Respiratory Care
Donald Darkin, President ? innovation & operations

Stock Performance Indicators

Did you try this?

Run Coins and Tokens Correlation Now

   

Coins and Tokens Correlation

Utilize digital token correlation table to build portfolio of cryptocurrencies across multiple exchanges
All  Next Launch Coins and Tokens Correlation
Currently Active Assets on Macroaxis
IVV   
Purchased over 100 shares of
a day ago
Traded for 278.27
IJR   
Purchased over 10K shares of
a day ago
Traded for 79.88
IJH   
Sold over 100 shares of
a day ago
Traded for 187.94
IJH   
Sold over 100 shares of
a day ago
Traded for 187.94
S   
Purchased over 400 shares of
a day ago
Traded for 6.46
Additionally take a look at Your Equity Center. Please also try Equity Analysis module to research over 250,000 global equities including funds, stocks and etfs to find investment opportunities.
Search macroaxis.com